Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections
Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...
Genor Biopharma Strikes Licensing Deal with TRC 2004 for Global Rights to GB261 Outside Greater China
China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity...
Degen Biopharmaceutical’s DG01 PROTAC Drug Receives NMPA Clearance for Solid Tumor Studies
Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in...
Chongqing Genrix’s GR1803 Earns Breakthrough Therapy Designation in China for RRMM Treatment
The Center for Drug Evaluation (CDE) of China has indicated that Chongqing Genrix Biopharmaceutical Co.,...
Lepu Biotechnology’s MRG003 Earns FDA Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has announced that...
Huadong Medicine Secures Exclusive Rights to Immunochina’s CAR-T Therapy in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has entered into a licensing agreement...
United Imaging Healthcare Launches Medical-Grade Hearing Aid uOrigin in China
United Imaging Healthcare Technology Co., Ltd (UIH), a leading player in the medical imaging and...
Bristol-Myers Squibb Terminates Partnership with Agenus on TIGIT/CD96 Bispecific Antibody
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its decision to end its...
GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance
GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life...
China’s CDE Seeks Public Comment on Latest Generic Drug Reference Preparations
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is currently...
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei...
Yantai Dongcheng Pharmaceutical Secures NMPA Nod for PSMA-Targeted Radiotherapeutic Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...
China’s CDE Releases Draft Guidelines for CAR-T Cell Therapy Clinical Trials
The Center for Drug Evaluation (CDE) in China has issued a draft proposal for “Technical...
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
HutchMed Establishes Global R&D Hub in Hong Kong Science Park to Accelerate Translational Medicine
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced the establishment of a global research...
Walvax Biotechnology’s Bivalent HPV Vaccine Earns WHO Pre-Qualification Status
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent...
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase...
Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS
China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...